円
1807.00
Apr 24
Business Description
Kyorin Pharmaceutical Co Ltd
NAICS : 325411
SIC : 2833
ISIN : JP3247090008
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.92 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.16 | |||||
Debt-to-EBITDA | 3.37 | |||||
Interest Coverage | 75.18 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.5 | |||||
Beneish M-Score | -2.28 | |||||
WACC vs ROIC |
Growth Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1 | |||||
3-Year EBITDA Growth Rate | -2.2 | |||||
3-Year EPS without NRI Growth Rate | -13.2 | |||||
3-Year Book Growth Rate | 0.7 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 52.31 | |||||
9-Day RSI | 50.47 | |||||
14-Day RSI | 50.72 | |||||
6-1 Month Momentum % | 1.85 | |||||
12-1 Month Momentum % | 5.16 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.53 | |||||
Quick Ratio | 1.4 | |||||
Cash Ratio | 0.4 | |||||
Days Inventory | 266.95 | |||||
Days Sales Outstanding | 131.76 | |||||
Days Payable | 69.13 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 2.88 | |||||
Dividend Payout Ratio | 0.77 | |||||
3-Year Dividend Growth Rate | -11.5 | |||||
Forward Dividend Yield % | 3.54 | |||||
5-Year Yield-on-Cost % | 2.27 | |||||
Shareholder Yield % | 3.16 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 42.92 | |||||
Operating Margin % | 4.08 | |||||
Net Margin % | 3.56 | |||||
FCF Margin % | -6.17 | |||||
ROE % | 3.38 | |||||
ROA % | 2.43 | |||||
ROIC % | 2.42 | |||||
ROC (Joel Greenblatt) % | 6.18 | |||||
ROCE % | 4.43 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 24.33 | |||||
PE Ratio without NRI | 26.87 | |||||
Shiller PE Ratio | 14.94 | |||||
PS Ratio | 0.86 | |||||
PB Ratio | 0.81 | |||||
Price-to-Tangible-Book | 0.85 | |||||
Price-to-Operating-Cash-Flow | 51.57 | |||||
EV-to-EBIT | 17.08 | |||||
EV-to-EBITDA | 17.08 | |||||
EV-to-Revenue | 0.87 | |||||
EV-to-FCF | -13.99 | |||||
Price-to-Projected-FCF | 0.84 | |||||
Price-to-Median-PS-Value | 0.68 | |||||
Price-to-Graham-Number | 1.01 | |||||
Price-to-Net-Current-Asset-Value | 1.52 | |||||
Earnings Yield (Greenblatt) % | 5.86 | |||||
FCF Yield % | -7.14 | |||||
Forward Rate of Return (Yacktman) % | 0.19 |